ライフサイエンスコーパス: ERbeta

1 ERbeta agonists promoted apoptosis of GBM cells, and mec

2 ERbeta also interacts with components of the cytoplasmic

3 ERbeta CKO in OLs prevented DPN-induced decrease in EAE

4 ERbeta has been proposed as a cancer brake that inhibits

5 ERbeta interfered with this recruitment by relocalizing

6 ERbeta is involved in migration of cortical neurons and

7 ERbeta is the target molecule of DPN because DPN treatme

8 ERbeta represses ERalpha-mediated activation of the ERE

9 ERbeta-EGFP cells expressed oxytocin more abundantly in

10 ERbeta-regulated factors are involved in cell adhesion,

11 ed in prostate cancer above Gleason grade 3, ERbeta is a potential drug target at the initial stage o

12 he apoptotic effect of 3beta-Adiol-activated ERbeta.

13 onclude that ligands specifically activating ERbeta could be useful pharmaceuticals in the treatment

14 onphosphorylatable, transcriptionally active ERbeta mutant retained antitumor activity but circumvent

15 oduced by splicing between exons 2 and 4, an ERbeta protein was expressed in nuclei of prostate epith

16 inhibition of enhanced ERbeta activity by an ERbeta-selective antagonist suppressed mouse ectopic les

17 In the present study, we created an ERbeta exon 3-deleted mouse (ERbeta-Deltaex3) and confir

18 pha agonist in males, whereas in females, an ERbeta agonist increased mEPSC frequency.

19 In males, an ERbeta agonist mimicked the postsynaptic effects of E2 t

20 n SJL/J mice, we evaluated the benefit of an ERbeta agonist as a modulator of neuroinflammation.

21 l development and examined the effects of an ERbeta-selective ligand (LY3201) with a combination of g

22 h doses decreased Ca(2+) currents through an ERbeta-mediated mechanism and simultaneously increased C

23 from ERbeta-Deltaex3 prostates, there was an ERbeta-dependent retardation of migration of activator p

24 he significant correlation between ADC7D and ERbeta-positive cell density suggests that ERbeta may pl

25 nto neural lineages, we compared control and ERbeta knockout (BERKO) mESCs at defined stages of neura

26 EB treatment in the GFP (GFP + EB) and ERbeta (ERbeta + EB) groups failed to improve episodic s

27 ession of the estrogen receptors ERalpha and ERbeta and demonstrate that the window for estradiol's b

28 e, lobular cancer expresses both ERalpha and ERbeta but with very few Ki67-positive cells.

29 ulates memory independently from ERalpha and ERbeta by activating JNK signaling, rather than ERK sign

30 group) tended to have comparable ERalpha and ERbeta ERE-mediated activities, similar chemical structu

31 mestrol (group 2) activated both ERalpha and ERbeta ERE-mediated activities.

32 The expression of the ERalpha and ERbeta estrogen receptors in the hippocampus may be impo

33 iproliferative and downregulated ERalpha and ERbeta expression in MCF-7 breast cancer cells.

34 u transgenic mice, we found that ERalpha and ERbeta expression, mammary tumorigenesis, and survival a

35 Individual quantification of ERalpha and ERbeta expression, rather than total ER levels, might en

36 elicited an increase in mammary ERalpha and ERbeta expression.

37 ERalpha and ERbeta form heterodimers binding DNA at specific oestrog

38 ms of estrogen signaling through ERalpha and ERbeta in EAE.

39 To examine the role of ERalpha and ERbeta in regulating transcription and learning, ovariec

40 Thus, our results indicate that ERalpha and ERbeta interact with hormone levels to regulate transcri

41 variectomized wild-type (WT) and ERalpha and ERbeta knockout (KO) mice were used.

42 PET of ERalpha and ERbeta levels could provide more insight in response to

43 Estrogen can bind to ERalpha and ERbeta localized at the plasma membrane as well as G-pro

44 microdomains of the DH, and that ERalpha and ERbeta physically interact with mGluR1, providing a mean

45 ERalpha and ERbeta regulation of gene transcription is further modul

46 Estrogen receptors ERalpha and ERbeta share considerable sequence homology yet exert op

47 he agonistic activity of EDCs on ERalpha and ERbeta via the luciferase reporter assay.

48 of classical estrogen receptors (ERalpha and ERbeta) and mGluR1a in mediating the effects of E2 on hi

49 ing FOXL2, RSPO1, CYP19A1, WNT4, ERalpha and ERbeta, after one postnatal year in the ovotestis.

50 intracellular estrogen receptors ERalpha and ERbeta, little is known about the role that the membrane

51 he classical estrogen receptors, ERalpha and ERbeta, to facilitate hippocampal memory in female mice.

52 s of the estrogen receptor (ER), ERalpha and ERbeta, were determined.

53 binding to 2 nuclear receptors, ERalpha and ERbeta, which differentially regulate gene transcription

54 diated by the estrogen receptors ERalpha and ERbeta, which function as ligand-activated transcription

55 The ER consists of 2 isoforms, ERalpha and ERbeta, which have distinct biologic functions.

56 itigenin with estrogen receptors ERalpha and ERbeta, with key coregulators (SRC3 and RIP140) and chro

57 udy, we report that IQGAP1 binds ERalpha and ERbeta.

58 ed transcriptional activation of ERalpha and ERbeta.

59 and either agonize or antagonize ERalpha and ERbeta.

60 that is, the estrogen receptors ERalpha and ERbeta.

61 butions to proliferation of both ERalpha and ERbeta.

62 fter imaging, and Ki-67, TUNEL, ERalpha, and ERbeta staining were performed on tumor tissue.

63 s suggest that both endogenous estradiol and ERbeta activation facilitate the ability of the IL-mPFC

64 drives breast cancer cell proliferation and ERbeta dampens this, the relative levels of these two ER

65 (IC50 values: 40 and 8 nM, respectively) and ERbeta (IC50 values: 19 and 15 nM).

66 stained), proliferative (Ki-67 stained), and ERbeta-positive cell densities, but ADC3D was not signif

67 s in a negative feedback loop in TGFbeta and ERbeta signaling pathways as evidenced by the potentiati

68 In 2008, another ERbeta mutant mouse was generated by deleting ERbeta exo

69 ere perform a rigorous validation of 13 anti-ERbeta antibodies, using well-characterized controls and

70 Using two different anti-ERbeta antibodies, we showed that an in-frame ligand bin

71 etermining the SUVs can be applied to assess ERbeta levels.

72 gh network prediction models have associated ERbeta with the EnR stress response, its role as regulat

73 on-neuroendocrine (presumably pre-autonomic) ERbeta-EGFP neurons predominated in the posterior PVN.

74 ogen receptor alpha (ERalpha), but not beta (ERbeta), mRNA, prevented the induction of priming by low

75 r estrogen receptor alpha (ERalpha) or beta (ERbeta) to ameliorate experimental autoimmune encephalom

76 he two receptors are estrogen receptor beta (ERbeta) and liver X receptor beta (LXRbeta).

77 ngaged mitochondrial estrogen receptor beta (ERbeta) as an antagonist in MCF7-BK cells, increasing re

78 Activation of estrogen receptor beta (ERbeta) but not ERalpha rescued synaptic potentiation in

79 rs DLX5 and EGR3 and estrogen receptor beta (ERbeta) directly controlling its expression in different

80 Loss of estrogen receptor beta (ERbeta) expression in the gut is associated with colorec

81 r alpha (ERalpha) or estrogen receptor beta (ERbeta) in the hippocampus of aged animals would restore

82 Estrogen receptor beta (ERbeta) is emerging as a critical factor in understandin

83 Estrogen receptor beta (ERbeta) is essential for migration of neurons and glial

84 By contrast, estrogen receptor beta (ERbeta) is expressed in many brain regions, yet few stud

85 In 1998, an estrogen receptor beta (ERbeta) knockout (KO) mouse was created by interrupting

86 is the precursor for estrogen receptor beta (ERbeta) ligands, 5AR inhibitors could potentially limit

87 Estrogen receptor beta (ERbeta) selective agonists are considered potential ther

88 colleagues show that estrogen receptor beta (ERbeta) signaling can act tumor-suppressive predominantl

89 ediated knockdown of estrogen receptor beta (ERbeta), but not ERalpha, abolished the effect of E2 on

90 tor alpha (ERalpha), estrogen receptor beta (ERbeta), or the G protein-coupled estrogen receptor (GPE

91 ects are mediated by estrogen receptor beta (ERbeta), which reduces chromatin occupancy and transcrip

92 Activation of estrogen receptor beta (ERbeta)-expressing neurons regulates the mammalian stres

93 pionitrile (DPN), an estrogen receptor beta (ERbeta)-specific agonist, and to a lesser extent 17alpha

94 lowing activation of estrogen receptor beta (ERbeta, ESR2).

95 The discovery of oestrogen receptor beta (ERbeta/ESR2) was a landmark discovery.

96 bition of microglial estrogen receptor-beta (ERbeta) function corrects the retinal abnormalities in f

97 pathways related to the association between ERbeta and tumor progression and metastasis.

98 a+/+ mice, indicating a relationship between ERbeta and FOXO3a expression.

99 of natural estrogen-like compounds that bind ERbeta with high selectivity.

100 Both ERbeta and LXRbeta have potent anti-inflammatory activit

101 As both ERbeta and LXRbeta are ligand-activated transcription fa

102 the 5AR inhibitor dutasteride requires both ERbeta and TGFbeta.

103 The regulation of FOXO3a by ERbeta in normal basal epithelial cells indicates a func

104 ominantly through the regulation of genes by ERbeta in the tumor, not in the microenvironment, and po

105 te markedly increased collagen production by ERbeta(-/-) fibroblasts.

106 ressed, but in the high-grade lobular cancer ERbeta was lost and ERalpha and Ki67 expression were abu

107 To this end, we selectively deleted ERbeta in OLs using the well-characterized Cre-loxP syst

108 Rbeta mutant mouse was generated by deleting ERbeta exon 3 which encodes the first zinc finger in the

109 al and 21 malignant human tissues, we detect ERbeta protein in testis, ovary, lymphoid cells, granulo

110 sent in ERbeta, but not in ERalpha, dictates ERbeta-specific activation of transcription and is requi

111 iproliferative and selectively downregulated ERbeta.

112 st), PPT (ERalpha-specific agonist) and DPN (ERbeta-specific agonist) on resistance arteries were att

113 nscription in U87 cells, suggesting elevated ERbeta expression in glioma might be induced by the hypo

114 embers and demonstrated loss of ESR2-encoded ERbeta expression in the MTC tumour.

115 estrogen receptor (ER) beta levels, enhanced ERbeta activity was detected in endometriotic tissues, a

116 otic tissues, and the inhibition of enhanced ERbeta activity by an ERbeta-selective antagonist suppre

117 viral vectors were used to express ERalpha, ERbeta, or green fluorescent protein (GFP) in the CA1 re

118 tology and immunohistochemistry for ERalpha, ERbeta, and progesterone receptor.

119 rent cell-signaling mechanisms from ERalpha, ERbeta, or 17beta-estradiol.

120 odulation of the estrogen receptors ERalpha, ERbeta, and GPR30.

121 Finally, we show that ERalpha, ERbeta, mGluR1, and ERK all reside within specialized me

122 ERalpha/ERbeta selectivity was also evaluated, but relatively fe

123 usly inoculated in the shoulder with ERalpha/ERbeta-expressing SKOV3 human ovarian cancer cells.

124 eleost estrogenic response, with the ERalpha:ERbeta ratio being of particular importance.

125 treatment in the GFP (GFP + EB) and ERbeta (ERbeta + EB) groups failed to improve episodic spatial m

126 the androgen receptor (AR), ERalpha (ESR1), ERbeta (ESR2), and progesterone receptor (PGR) genes.

127 Since GBM express ERbeta, a second receptor for estrogen, targeting ERbeta

128 roximately 80% of epithelial cells expressed ERbeta.

129 ficial chromosome transgenic mice expressing ERbeta identified by enhanced green fluorescent protein

130 isoflavones, especially of high affinity for ERbeta.

131 or ERs, with a 3.5 times higher affinity for ERbeta.

132 s has been shown to have a high affinity for ERbeta.

133 tors (ERs) including beneficial affinity for ERbeta.

134 ivation of transcription and is required for ERbeta-dependent inhibition of cancer cell growth in cul

135 Phosphorylation of Y36 was required for ERbeta-mediated coactivator recruitment to ERbeta target

136 lobular cancer and (ii) a potential role for ERbeta agonists in preventing in situ ductal cancers fro

137 s to catecholamines reveals a novel role for ERbeta in controlling browning of adipose tissue.

138 r imaging and shows relative selectivity for ERbeta.

139 r imaging and shows relative selectivity for ERbeta.

140 Moreover, with nuclear extracts from ERbeta-Deltaex3 prostates, there was an ERbeta-dependent

141 Furthermore, ERbeta(-/-) mice were characterized by significantly red

142 e of estradiol (nonselective) and genistein (ERbeta-selective), respectively.

143 adiol (nonspecific ER agonist) or genistein (ERbeta-selective agonist).

144 to decrease EAE clinical symptoms in global ERbeta-null mice.

145 Concurrently, COX-2 positively impacts ERbeta action through its effect on the expression of a

146 -EGFP and found developmental alterations in ERbeta expression within the cortex, hippocampus, and hy

147 etic analysis methods to quantify changes in ERbeta availability with (18)F-FHNP PET.

148 ung female mice, NR1 density is decreased in ERbeta-PVN dendrites thus reducing NMDA receptor activit

149 We also report a sex difference in ERbeta in the bed nucleus of the stria terminalis, with

150 developmental changes and sex differences in ERbeta indicate a mechanism through which estrogens migh

151 emonstrate chemoarchitectural differences in ERbeta neurons of the mouse PVN that are different from

152 enhanced green fluorescent protein (EGFP) in ERbeta-containing cells were implanted with osmotic mini

153 brain-derived neurotrophic factor levels in ERbeta CKO mice.

154 in cells of oligodendrocyte (OL) lineage in ERbeta ligand-mediated neuroprotection.

155 r-intensified immunogold (SIG) was mainly in ERbeta-EGFP dendrites.

156 ian target of rapamycin signaling pathway in ERbeta CKO mice.

157 ation of a tyrosine residue (Y36) present in ERbeta, but not in ERalpha, dictates ERbeta-specific act

158 nce NMDA receptor NR1 subunit trafficking in ERbeta-containing PVN neurons.

159 aged females, NR1 density is upregulated in ERbeta-PVN dendrites and ultimately leads to the neurohu

160 samples, elevated phosphorylation of Y36 in ERbeta correlated with high levels of c-ABL but low EYA2

161 eral identified NOTCH1 regulators, including ERbeta, is frequently compromised in skin, head and neck

162 Experimentally increased ERbeta expression or treatment with ERbeta agonists inhi

163 of hypoxia inducible factor (HIF) increased ERbeta transcription in U87 cells, suggesting elevated E

164 lation of HIF-1alpha stability that involves ERbeta-mediated transcriptional regulation of PHD2 and t

165 active Notch1 through a mechanism involving ERbeta to protect the endothelium in TNFalpha-induced in

166 n channel expression, in a process involving ERbeta.

167 Furthermore, a keratinocyte ERbeta-dependent program of gene expression is subverted

168 ands, 5AR inhibitors could potentially limit ERbeta activation, which maintains prostate tissue homeo

169 ith preferential binding affinity for medaka ERbeta subtypes, which are highly expressed in male meda

170 y through agonistic effects at mitochondrial ERbeta.

171 pressing EGFP under the control of the mouse ERbeta promoter (ERbeta-EGFP) to examine the chemical ar

172 , we created an ERbeta exon 3-deleted mouse (ERbeta-Deltaex3) and confirmed that the only observable

173 Tamoxifen, a nongenomic ERbeta agonist, down-regulates Sost expression in vitro

174 invasive ductal cancers neither ERalpha nor ERbeta was expressed, but in the high-grade lobular canc

175 found that ERalpha ligand treatment, but not ERbeta ligand treatment, decreased expression of the che

176 vity of ER (estrogen receptor)-alpha but not ERbeta through the modulation of ERalpha phosphorylation

177 role for inflammatory cell ERalpha, but not ERbeta, in poor healing associated with an altered cytok

178 g immunohistochemistry, we found that 90% of ERbeta-immunoreactivity (-ir) colocalized with EGFP.

179 of COX-2 on the tissue-protective action of ERbeta.

180 Importantly, activation of ERbeta inhibited angiogenesis and lymphangiogenesis, pos

181 In Granta-519 MCL tumors, activation of ERbeta reduced expression of BAFF and GRB7, 2 important

182 not clear whether the antitumor activity of ERbeta can be mobilized in breast cancer cells.

183 clusion:(18)F-FHNP PET enables assessment of ERbeta availability in tumor-bearing rats.

184 )pyridin-3-ol ((18)F-FHNP) for assessment of ERbeta levels with PET.

185 Emerging evidence suggests a decline of ERbeta expression in various peripheral cancers.

186 could be reversed by lentiviral delivery of ERbeta to the hippocampus.

187 ompare expression levels and distribution of ERbeta in the male and female mouse forebrain on the day

188 tive analysis, we mapped the distribution of ERbeta-EGFP and found developmental alterations in ERbet

189 show that the growth-suppressing effects of ERbeta agonist are also valid for human B-cell lymphomas

190 Here, we tested the effects of ERbeta targeting on LHON mitochondrial defective metabol

191 However, the effects of ERbeta-specific ligands on human or murine pathogenic im

192 T cells only, indicating that expression of ERbeta by these cells is crucial for the observed therap

193 Expression of ERbeta failed to improve cognition and was associated wi

194 Sexually dimorphic expression of ERbeta in the MePD was observed on PND 0, with higher le

195 was associated with increased expression of ERbeta in the nuclei of neurons in the sympathetic gangl

196 in males there was very little expression of ERbeta in the SAT and very little expression of the beta

197 In addition, the expression of ERbeta, FOXO3a and PUMA is comparable and higher in beni

198 sal epithelial cells indicates a function of ERbeta in cell differentiation and maintenance of cells

199 These results suggest that one function of ERbeta is to regulate ERalpha-mediated transcription in

200 uestions about the physiological function of ERbeta.

201 Furthermore, this gain of ERbeta function enhances epithelial-mesenchymal transiti

202 Notably, gain of ERbeta function stimulated the progression of endometrio

203 p into sustained ectopic lesions via gain of ERbeta function.

204 e humans, rodents express a novel isoform of ERbeta (mERbeta2) with a modified ligand-binding domain

205 tified ERbeta5 as the predominant isoform of ERbeta in human glioma and its expression was significan

206 pported by our observations that knockout of ERbeta under conditions of low estradiol allowed ERalpha

207 which display unprecedentedly high levels of ERbeta selectivity for this class of compounds, both in

208 We conclude that very little of ERbeta transcriptional activity depends on binding to cl

209 r higher, where there is substantial loss of ERbeta, FOXO3a and PUMA.

210 Moreover, the ventral prostate of ERbeta-/- mice had decreased expression of FOXO3a and PU

211 Here we investigated the potential role of ERbeta expression in cells of oligodendrocyte (OL) linea

212 l probe for helping to elucidate the role of ERbeta in cancer cells.

213 ollagen content was decreased in the skin of ERbeta(-/-) mice, despite markedly increased collagen pr

214 2 had a compound-specific negative effect on ERbeta/ligand-mediated activity and ER target genes when

215 reast cancer cells containing ERalpha and/or ERbeta.

216 osynthesis in mice lacking either ERalpha or ERbeta.

217 Knockdown of FOXO3a or ERbeta expression abolished the increase of PUMA in resp

218 Sost down-regulation by strain or ERbeta activation is prevented by MEK/ERK blockade.

219 is a highly proliferative, ERalpha-positive, ERbeta-negative disease, lobular cancer expresses both E

220 the synthesis and evaluation of a potential ERbeta-selective PET tracer: 2-(18)F-fluoro-6-(6-hydroxy

221 er the control of the mouse ERbeta promoter (ERbeta-EGFP) to examine the chemical architecture of PVN

222 to examine the chemical architecture of PVN ERbeta cells.

223 ytochemistry, but careful exploration of PVN ERbeta neurons in mice has been hindered by a lack of sp

224 of fluorogold revealed that the rostral PVN ERbeta-EGFP cells are neuroendocrine neurons whereas non

225 rmacokinetic models were applied to quantify ERbeta availability in the tumor.

226 The most suitable parameter to quantify ERbeta expression is the Ki However, a simplified static

227 that Ki is a suitable parameter to quantify ERbeta expression.

228 -cells from wild-type and oestrogen receptor ERbeta-/- mice, we found that exposure to increasing dos

229 dentify a signaling circuitry that regulates ERbeta-specific antitumor activity and has potential as

230 roprotection in EAE, by selectively removing ERbeta from either of these cell types using Cre-loxP ge

231 diated via ERbeta signaling does not require ERbeta on either astrocytes or neurons, whereas neuropro

232 eatment of EAE mice with LY3201, a selective ERbeta agonist provided by Eli Lilly, resulted in marked

233 A 3-day-treatment with a selective ERbeta agonist, LY3201, induced browning of SAT in 1-yea

234 Liquiritigenin showed ERbeta selectivity in competitive binding assay and isol

235 active Notch1 was abrogated after silencing ERbeta.

236 mice has been hindered by a lack of specific ERbeta antisera.

237 the presence of phosphorylated Y36-specific ERbeta was strongly associated with both disease-free an

238 phosphorylation status of Y36 and subsequent ERbeta function.

239 enous immune surveillance for cell survival, ERbeta interacts with cellular apoptotic machinery in th

240 ulates cell proliferation and cell survival, ERbeta promotes apoptosis.

241 Importantly, synthetic ERbeta-specific ligands acting directly on CD4(+) T cell

242 herapeutic effect of the selective synthetic ERbeta agonist LY500307 using in vitro and in vivo GBM m

243 In this article, we show that the synthetic ERbeta-specific ligand 4-(2-phenyl-5,7-bis[trifluorometh

244 a, a second receptor for estrogen, targeting ERbeta with a selective agonist may be a potential novel

245 These results suggest that targeting ERbeta with agonists may be valuable in the treatment of

246 Thus, targeting ERbeta may become a therapeutic strategy for LHON specif

247 sed monoclonal PPZ0506, specifically targets ERbeta in immunohistochemistry.

248 We conclude that ERbeta agonists should be considered as new targets for

249 We conclude that ERbeta induces apoptosis of prostate cancer cells by inc

250 2 or DPN, providing functional evidence that ERbeta interacts with metabotropic glutamate receptor 1a

251 Results support emerging evidence that ERbeta subtypes are critically involved in the teleost e

252 We found that ERbeta but not ERalpha is strongly expressed in the DR a

253 n human prostate cancer cells, we found that ERbeta causes apoptosis by increasing the expression of

254 We found that ERbeta was induced in embryoid bodies (EBs) and neural p

255 In this study, we found that ERbeta, but not ERalpha, is expressed in microglia.

256 We also show by immunohistochemistry that ERbeta is expressed in primary MCL tissue.

257 We report that ERbeta regulates the ligand (3beta-adiol)-dependent tran

258 ng disseminating Raji BL cells, we show that ERbeta activation reduces dissemination of grafted Raji

259 In the present study we show that ERbeta influences browning of subcutaneous adipose tissu

260 Together these results show that ERbeta plays a key role in sexual behavior regulation an

261 Our data show that ERbeta-selective agonists, by modulating the immune syst

262 We also showed that ERbeta localize to the mitochondria of RGCs.

263 Our data suggest that ERbeta is an important component for differentiation int

264 d ERbeta-positive cell density suggests that ERbeta may play an important role as a therapeutic indic

265 The ERbeta agonists 2,3-bis(4-hydroxyphenyl)-propionitrile a

266 hydrocarbon receptor activation enhanced the ERbeta ligand-mediated expansion of IL-10-producing T ce

267 of a number of steroidogenic enzymes in the ERbeta ligand metabolic pathway.

268 n prostate epithelium was not altered in the ERbeta-Deltaex3 mouse.

269 ng domain and C terminus were present in the ERbeta-Deltaex3 protein.

270 or the beneficial myelination effects of the ERbeta ligand DPN in chronic EAE mice.

271 -(1H)-pyrazol-1,3,5-triyl]tris-phenol or the ERbeta antagonist PTHPP has no effect.

272 ression of FOXO3a and PUMA compared with the ERbeta+/+ mice, indicating a relationship between ERbeta

273 tment of PC3, 22Rv1 and LNCaP cells with the ERbeta-specific ligands 3beta-Adiol (5alpha-androstane-3

274 BEs preferentially bind to ERbeta, but their ERbeta-potency selectivity in gene stimulation (340- to

275 In addition, these ERbeta-specific ligands promoted the induction and maint

276 Finally, these ERbeta-selective agonists were found to inhibit prolifer

277 ar mechanisms underlying the effects of this ERbeta ligand on the central nervous system are uncertai

278 findings demonstrate that signaling through ERbeta in OLs is essential for the beneficial myelinatio

279 Thus, ERbeta-specific ligands targeting pathogenic Th17 cells

280 , estradiol (E2), BEs preferentially bind to ERbeta, but their ERbeta-potency selectivity in gene sti

281 r ERbeta-mediated coactivator recruitment to ERbeta target promoters.

282 vels of FOXO3a were increased in response to ERbeta expression or treatment of PC3, 22Rv1 and LNCaP c

283 Furthermore, compared with total ERbeta, the presence of phosphorylated Y36-specific ERbe

284 Here, upregulation of wild-type ERbeta (ERbeta1) or treatment with ERbeta agonists enhan

285 By using ERbeta-deficient mice, we now demonstrate that this inhi

286 This mechanism potentially supports using ERbeta agonists as HDAC modulators to treat cardiac dise

287 how that neuroprotection in EAE mediated via ERbeta signaling does not require ERbeta on either astro

288 Here, we determined whether ERbeta on astrocytes or neurons could mediate neuroprote

289 To examine whether ERbeta influences differentiation of mouse embryonic ste

290 eus of P21, but not P0 or P4, mice, in which ERbeta-EGFP-immunoreactive cells were densely clustered

291 olII) recruitment to the NOTCH1 locus, while ERbeta controls NOTCH1 transcription through RNA PolII p

292 also correlated (r(2) = 0.47; P = 0.04) with ERbeta expression.

293 0.46, P = 0.03) and was not associated with ERbeta expression (rho = 0.21, P = 0.33).

294 These effects were abolished in cells with ERbeta knockdown by silencing receptor expression or by

295 use, we found a moderate colocalization with ERbeta-ir (48 +/- 16%) in the middle PVN.

296 estrogen receptor alpha-ir colocalized with ERbeta-EGFP at low levels (15 +/- 3%).

297 litis amelioration was canceled in mice with ERbeta-deficient CD4(+) T cells only, indicating that ex

298 wild-type ERbeta (ERbeta1) or treatment with ERbeta agonists enhanced apoptosis in breast cancer cell

299 ncreased ERbeta expression or treatment with ERbeta agonists inhibited proliferation of SCC cells and

300 The Ki values correlated well with ERbeta expression but not with ERalpha, confirming that